SLC5A2 and myocardial infarction: SGLT2 inhibitors did not increase the risk of myocardial infarction (RR: 0.95; 95% CI 0.78–1.16; p = 0.65; moderate SOE), which was consistent with SGLT2 inhibitor subtypes (RRdapagliflozin: 0.95; 95% CI 0.74–1.23; p = 0.71; RRcanagliflozin: 0.97; 95% CI 0.71–1.33; p = 0.87; RRempagliflozin: 0.62; 95% CI 0.11–3.37; p = 0.58) (Additional file 1: Figure S4).